Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
Authors
Keywords
-
Journal
Blood Advances
Volume 4, Issue 22, Pages 5825-5835
Publisher
American Society of Hematology
Online
2020-12-04
DOI
10.1182/bloodadvances.2020003314
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication
- (2020) Bridget K. Marcellino et al. Clinical Lymphoma Myeloma & Leukemia
- The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden
- (2019) Srdan Verstovsek et al. BLOOD
- Prognostic impact of RAS-pathway mutations in patients with myelofibrosis
- (2019) Fabio P. S. Santos et al. LEUKEMIA
- Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
- (2019) Francesca Palandri et al. CANCER
- Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis
- (2018) Lucia Masarova et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
- (2018) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis
- (2018) Alessandro M. Vannucchi et al. HAEMATOLOGICA
- Classification and Personalized Prognosis in Myeloproliferative Neoplasms
- (2018) Jacob Grinfeld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
- (2018) Annalisa Pacilli et al. Blood Cancer Journal
- Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs
- (2017) Allison H. Scotch et al. LEUKEMIA RESEARCH
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
- (2014) Raajit Rampal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2013) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
- (2013) Moshe Talpaz et al. Journal of Hematology & Oncology
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- What are RBC-transfusion-dependence and -independence?
- (2010) R.P. Gale et al. LEUKEMIA RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started